A medical spa sells a menu, and the menu's lines have nothing in common financially: injectables carry product cost that dominates the margin and expires on the shelf; energy devices carry six-figure financing that must be paid whether or not the schedule fills; body contouring runs on a device with a consumable per treatment; skincare retail is inventory with a shelf life and an attach rate; memberships are cash received for services not yet delivered. The income statement averages them into one margin, and the average hides which lines are carrying the business and which are being carried.
What goes into a service-line profit and loss statement?
Revenue by line, on the basis the line earns it. Injectable and device treatments at the fee collected, net of promotions and discounts attributed to the line that ran them; retail at the sale price net of returns; memberships recognized as the included services are delivered and the discount is used, with the unearned balance as a liability; packages and prepaid series recognized per treatment delivered; gift cards as a liability until redeemed.
Product cost per treatment, measured — not the vendor's list. For injectables, the cost per unit or per syringe at the price actually paid after rebates and loyalty programs, times units actually used per treatment from the clinical record, plus the waste — opened vials not fully used, expired product, and the dose variance between what was charged and what was injected; waste in unmeasured practices runs 8 to 15 percent of injectable product cost, which on US$600,000 of product is US$50,000 to US$90,000 a year that the line's margin is pretending does not exist.
Provider compensation inside the line. The injector's or technician's wage for the treatment time plus commission on the service, attributed to the treatment — because a commission structure that pays 20 percent on service revenue is a 20-point reduction in every line's margin, and lines with lower revenue per hour feel it most.
Device cost charged to the line that uses it. Lease or financing payment, maintenance contract, consumables per treatment (tips, applicators, gels, cartridges), and training — divided across the treatments the device actually performed; a US$140,000 device financed at US$2,700 a month that performs 25 treatments a month carries US$108 of financing per treatment before consumables; at 60 treatments it carries US$45.
Allocated costs by driver. Room time by scheduled treatment hours, front desk and booking by appointment count, marketing by the campaigns that drove each line's bookings where attributable and by revenue otherwise, medical director and good-faith-exam cost by treatment type that requires it, and administration by direct cost.
Why are injectables usually the engine, and where do they leak?
Injectables earn on volume and product discipline. A neurotoxin treatment at US$520 collected with 45 units at a net cost of US$5.20 per unit (US$234), a 20 percent commission (US$104), thirty minutes of injector wage (US$28), and US$40 of allocated room and front-desk cost leaves about US$114 of contribution — a 22 percent margin that improves with volume discounts and worsens with waste and promotions. Filler at US$750 per syringe with a US$290 product cost follows the same arithmetic at a higher ticket.
The leaks. Waste that is not measured; promotions that discount the highest-volume line without measuring incrementality; rebate and loyalty-program income recorded as a general credit instead of reducing the line's product cost; dose creep where the treatment uses more units than the price assumed; and provider commission on gross service revenue including the promotion, which pays the injector on a discount the practice funded.
How do energy devices and body contouring fail on utilization?
A device is a fixed cost waiting for a schedule. The financing payment is due monthly; the margin depends on treatments per month; the vendor's projection — forty treatments a month at US$400 — assumed demand the practice never generated. At fifteen treatments the financing alone is US$180 per treatment and the line loses money before consumables and provider time.
Body contouring is the most common losing line. Long treatment times, consumable cost per session, heavy promotion to drive volume, provider time at a technician wage plus commission, and a device bought at the top of a demand cycle; the line's profit and loss statement at measured utilization is often negative on every treatment, and the practice keeps it because the device is financed and the menu looks incomplete without it.
The fix is a decision, not a hope. Reprice to a contribution-positive level if demand holds; consolidate two devices into one and redeploy or sell the second; or exit the line and settle the financing — each modeled against the subsidy of continuing.
How do retail and memberships behave?
Skincare retail is inventory economics. Cost of goods at 40 to 55 percent of retail, shelf life by product, shrink, and an attach rate — the share of treatment visits that include a retail purchase — that is the line's growth lever; a line with a 60 percent product margin and an 18 percent attach rate is a margin opportunity that marketing and provider prompts can move, while the inventory on the shelf is cash and expiry risk that purchasing discipline controls.
Memberships are a liability first and revenue second. Monthly fees collected for included services and discounts; the unearned portion sits as deferred revenue until delivered; breakage — included services never used — is recognized on a defined policy, not assumed; churn by cohort decides lifetime value; and the member's discounted treatments reduce the margin of the lines they are applied to, which the line-level statement must show by attributing the membership discount to the treatment line.
What decisions does the line-level view enable?
Menu and pricing. Lines below contribution after device and commission cost are repriced, repackaged, or retired; the injectable line's waste program and promotion governance are funded because the arithmetic is visible; retail attach-rate targets are set by provider.
Compensation. Commission moved from gross service revenue to contribution or to net-of-promotion revenue, with differentials for high-margin lines, so providers' incentives match the practice's margin.
Capital. The next device purchase modeled on the practice's own demand evidence and a payback at realistic utilization, with a decision gate at six months.
Multi-location. The same line-level statement by location, because a line can earn at one site and lose at another, and the device fleet is sized to the portfolio rather than to each site's wish list.
Why is this CFO work?
Measured product cost with waste requires inventory and clinical records joined to purchasing; device cost per treatment requires financing schedules against scheduling data; membership and package accounting is deferred-revenue work most practices have never done; provider commission attribution is a compensation design; and the menu, pricing, and capital decisions are the owners' to make with the numbers in front of them. The medical director and the lead injector own the clinical protocols and the client experience; the CFO owns the economics of every line.
Worked example
A three-location aesthetics brand, US$6.4 million revenue, two energy devices per site, a membership program with 1,900 members.
| Line | Revenue | Product / consumable cost | Provider wage + commission | Device cost | Allocated | Contribution | Margin |
|---|---|---|---|---|---|---|---|
| Injectables (neurotoxin + filler) | US$3,120,000 | US$1,390,000 (waste 11%) | US$780,000 | — | US$420,000 | US$530,000 | 17% |
| Energy devices (laser, skin tightening) | US$1,180,000 | US$95,000 | US$310,000 | US$290,000 | US$190,000 | US$295,000 | 25% |
| Body contouring | US$640,000 | US$140,000 | US$210,000 | US$260,000 | US$110,000 | −US$80,000 | −13% |
| Skincare retail | US$560,000 | US$290,000 | US$45,000 (commission) | — | US$60,000 | US$165,000 | 29% |
| Memberships (fees recognized) | US$620,000 | — | — | — | US$70,000 | US$550,000 before discounts attributed; discounts of US$410,000 sit in the treatment lines | — |
| Wellness / IV | US$280,000 | US$95,000 | US$90,000 | — | US$50,000 | US$45,000 | 16% |
Illustrative figures for a hypothetical organization; not a client's data.
Three findings changed the brand's year: injectable waste at 11 percent was US$153,000 of product thrown away or mis-dosed, and a waste protocol with unit tracking cut it to 4 percent; body contouring lost US$80,000 after device financing on every treatment, and consolidating from six devices to three across the three sites (with two sold) turned the line to +US$35,000; and membership discounts of US$410,000 had been invisible in the treatment lines, which explained why injectable margin was lower than the owners expected — the membership was repriced and its discount narrowed on the highest-cost treatments. Provider commission moved from gross service revenue to net-of-promotion revenue in the same quarter.